|
|
|
Insider
Information: |
Bienaime Jean Jacques |
Relationship: |
|
City: |
Palo Alto |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
8 |
|
Direct
Shares |
540,054 |
|
Indirect Shares
|
247,533 |
|
|
Direct
Value |
$43,092,104 |
|
|
Indirect Value
|
$21,938,850 |
|
|
Total
Shares |
787,587 |
|
|
Total
Value |
$65,030,954 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
1
|
Stock
price went up :
|
1
|
0
|
Stock
price went down : |
1
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
Percentage
Gain/Loss : |
-13.1%
|
-5.5%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Biomarin Pharmaceutical Inc |
BMRN |
Director |
2024-05-20 |
473,792 |
2024-05-20 |
247,533 |
Premium* |
|
Neurogesx Inc |
NGSX |
Director |
2011-07-26 |
21,748 |
|
0 |
Premium* |
|
InterMune Inc |
ITMN |
Director |
2014-09-29 |
0 |
2012-04-06 |
0 |
Premium* |
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2014-05-16 |
706 |
2013-05-28 |
0 |
Premium* |
|
Immunic Inc |
IMUX |
Director |
2018-09-24 |
18,500 |
2001-04-23 |
0 |
Premium* |
|
Incyte Corp |
INCY |
Director |
2023-06-14 |
15,493 |
|
0 |
Premium* |
|
Immunome Inc. |
IMNM |
|
2024-05-21 |
9,615 |
|
0 |
Premium* |
|
Keros Therapeutics, Inc. |
KROS |
|
2024-06-01 |
200 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
853 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 16 of 35
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
PTLA |
Portola Pharmaceuticals I... |
Director |
|
2014-05-16 |
4 |
S |
$22.03 |
$22,030 |
D/D |
(1,000) |
706 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2010-09-08 |
4 |
S |
$22.22 |
$22,220 |
D/D |
(1,000) |
95,067 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2007-09-19 |
4 |
AS |
$23.00 |
$230,000 |
D/D |
(10,000) |
6,695 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2013-04-30 |
4 |
A |
$23.21 |
$21,256 |
D/D |
916 |
120,317 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2007-09-25 |
4 |
AS |
$24.00 |
$240,000 |
D/D |
(10,000) |
6,695 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2007-09-28 |
4 |
AS |
$25.00 |
$480,175 |
D/D |
(19,207) |
7,488 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2007-10-01 |
4 |
AS |
$25.10 |
$19,904 |
D/D |
(793) |
6,695 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
Director |
|
2014-03-06 |
4 |
S |
$25.15 |
$25,150 |
D/D |
(1,000) |
1,706 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2010-11-03 |
4 |
S |
$25.46 |
$101,824 |
D/D |
(4,000) |
93,567 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2010-11-02 |
4 |
S |
$25.64 |
$89,750 |
D/D |
(3,500) |
93,567 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2011-05-05 |
4 |
S |
$25.64 |
$5,128 |
D/D |
(200) |
87,993 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2010-11-08 |
4 |
S |
$25.78 |
$51,569 |
D/D |
(2,000) |
93,567 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2011-05-04 |
4 |
S |
$25.84 |
$70,547 |
D/D |
(2,700) |
88,193 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2011-05-10 |
4 |
S |
$25.87 |
$10,346 |
D/D |
(400) |
87,593 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2010-11-18 |
4 |
S |
$25.99 |
$25,988 |
D/D |
(1,000) |
93,567 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2016-11-21 |
4 |
OE |
$26.49 |
$1,847,519 |
D/D |
69,744 |
240,426 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2016-11-22 |
4 |
OE |
$26.49 |
$1,847,492 |
D/D |
69,743 |
240,425 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2020-04-07 |
4 |
OE |
$26.49 |
$26,490 |
D/D |
1,000 |
298,213 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2021-01-27 |
4 |
OE |
$26.49 |
$220,741 |
D/D |
8,333 |
303,885 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2021-01-28 |
4 |
OE |
$26.49 |
$220,741 |
D/D |
8,333 |
303,885 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2021-01-29 |
4 |
OE |
$26.49 |
$220,768 |
D/D |
8,334 |
303,886 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2021-02-17 |
4 |
OE |
$26.49 |
$211,920 |
D/D |
8,000 |
303,552 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2021-02-18 |
4 |
OE |
$26.49 |
$185,430 |
D/D |
7,000 |
302,552 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2021-02-19 |
4 |
OE |
$26.49 |
$185,430 |
D/D |
7,000 |
302,552 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2021-03-11 |
4 |
OE |
$26.49 |
$185,430 |
D/D |
7,000 |
302,652 |
0 |
- |
|
853 Records found
|
|
Page 16 of 35 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|